Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 9/20 | 0.73 |
| ▸ | BCHE known ✓ | P06276 | 3/20 | 0.62 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.56 |
| ▸ | LCK known ✓ | P06239 | 1/20 | 0.53 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.62 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.62 |
| ▸ | NOS1 | P29475 | 1/20 | 0.56 |
| ▸ | NOS2 | P35228 | 1/20 | 0.56 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30207536 | 0.98 | MAOB (0.70) | MAOBBCHECYP4F2CYP4A11NOS1 | |
| SCHEMBL538599 | 0.98 | MAOB (0.70) | MAOBBCHECYP4F2CYP4A11NOS1 | |
| SCHEMBL110797 | 0.87 | MAOB (0.70) | MAOBNOS1NOS2MAOA | |
| Hydrochloric Acid SCHEMBL70370 | 0.86 | CYP4F2 (0.68) | MAOBBCHECYP4F2CYP4A11 | |
| Hydrochloric Acid SCHEMBL921962 | 0.85 | MAOB (1.00) | MAOBBCHEMAOA | |
| SCHEMBL214186 | 0.85 | MAOB (0.67) | MAOBBCHECYP4F2CYP4A11MAOA | |
| SCHEMBL3273603 | 0.85 | MAOB (0.67) | MAOBBCHECYP4F2CYP4A11MAOA | |
| SCHEMBL15761340 | 0.84 | BCHE (0.70) | MAOBBCHECYP4F2CYP4A11MAOA | |
| SCHEMBL921785 | 0.84 | MAOB (0.85) | MAOBMAOA | |
| SCHEMBL1268719 | 0.84 | MAOB (0.81) | MAOBBCHECYP4F2CYP4A11MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240050438-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | ATHENEX, INC. | 2024-02-15 | — | — | US | disclosed |
| US-20220119347-A1 | BIARYL COMPOSITIONS IN COMBINATION WITH TAMOXIFEN AND METHODS FOR MODULATING A KINASE CASCADE | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2022-04-21 | — | — | US | disclosed |
| US-20210252008-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2021-08-19 | — | — | US | disclosed |
| US-10626112-B2 | Heterocyclic sulfonamide derivative and medicine comprising same | EA PHARMA CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| CN-106458952-B | Heterocycle sulfamide derivatives and drug containing the heterocycle sulfamide derivatives | EA制药株式会社 | 2019-09-27 | — | — | CN | disclosed |
| EP-3101015-B1 | HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME | EA PHARMA CO LTD (JP) | 2019-09-18 | — | — | EP | disclosed |
| US-10196357-B2 | Biaryl compositions and methods for modulating a kinase cascade | ATHENEX, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170196874-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | OAKTREE FUND ADMINISTRATION, LLC | 2017-07-13 | — | — | US | disclosed |
| US-9655903-B2 | Compositions and methods of treating cell proliferation disorders | ATHENEX, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9580387-B2 | Biaryl compositions and methods for modulating a kinase cascade | ATHENEX, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20070197783-A1 | Compositions and methods of treating cell proliferation disorders | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070015752-A1 | Biaryl compositions and methods for modulating a kinase cascade | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2007-01-18 | — | — | US | disclosed |
| US-20060160800-A1 | Morpholino-2-[6-(2-Ethoxy-phenyl)-pyridin-3-yl]-benzyl)-acetamide compound; as anti-proliferative agents, for treating mammals | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2006-07-20 | — | — | US | disclosed |
| WO-2006071960-A2 | COMPOSITIONS AND METHODS OF TREATING CELL PROLIFERATION DISORDERS | KINEX PHARMACEUTICALS, LLC (US) | 2006-07-06 | — | — | WO | disclosed |
| US-5234946-A | Anticholesterol, antilipemic | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1993-08-10 | — | — | US | disclosed |
| EP-0318860-B1 | SUBSTITUTED ALKYLAMINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1993-06-16 | — | — | EP | disclosed |
| US-5098900-A | Reducing contractions in smooth muscles | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1992-03-24 | — | — | US | disclosed |
| EP-0186817-B1 | 3(2H)PYRIDAZINONE, PROCESS FOR ITS PREPARATION AND ANTI-ALLERGIC AGENT CONTAINING IT | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1989-08-02 | — | — | EP | disclosed |
| EP-0318860-A2 | Substituted alkylamine derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1989-06-07 | — | — | EP | disclosed |
| EP-0186817-A1 | 3(2H)pyridazinone, process for its preparation and anti-allergic agent containing it | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1986-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119347-A1 | BIARYL COMPOSITIONS IN COMBINATION WITH TAMOXIFEN AND METHODS FOR MODULATING A KINASE CASCADE | MAP3K2, MAP3K6, MAP3K8 | MAOB 2496/4885BCHE 2484/4885MAOA 3201/4885 |
| US-20070015752-A1 | Biaryl compositions and methods for modulating a kinase cascade | MAP3K3, MAP3K2, MAP3K20 | MAOB 2889/4885BCHE 2535/4885MAOA 3420/4885 |
| US-20060160800-A1 | Morpholino-2-[6-(2-Ethoxy-phenyl)-pyridin-3-yl]-benzyl)-acetamide compound; as anti-proliferative agents, for treating mammals | MKI67, PCNA, CCAR2 | MAOB 4117/4885BCHE 4761/4885MAOA 3847/4885 |
| US-20240050438-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | MAP3K3, MAP3K2, MAP3K20 | MAOB 2889/4885BCHE 2535/4885MAOA 3420/4885 |
| US-20170196874-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | MAP3K3, MAP3K2, MAP3K20 | MAOB 2889/4885BCHE 2535/4885MAOA 3420/4885 |
| US-10196357-B2 | Biaryl compositions and methods for modulating a kinase cascade | MAP3K2, MAP3K3, MAP3K6 | MAOB 1540/4885BCHE 2384/4885MAOA 3068/4885 |
| US-20210252008-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | MAP3K3, MAP3K2, MAP3K20 | MAOB 2889/4885BCHE 2535/4885MAOA 3420/4885 |
| US-10626112-B2 | Heterocyclic sulfonamide derivative and medicine comprising same | TRPA1, TRPV1, TRPV2 | MAOB 2570/4885BCHE 3960/4885MAOA 2353/4885 |
| US-20070197783-A1 | Compositions and methods of treating cell proliferation disorders | MKI67, CCNC, CCNA1 | MAOB 2994/4885BCHE 3667/4885MAOA 3240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.